EWA
XLRN

Evolution Wealth Advisors’s Acceleron Pharma XLRN Stock Holding History

Evolution Wealth Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-47
Closed -$8K – 676
2021
Q3 		$8K Sell
47
-83
-64% -$10.9K ﹤0.01% 443
2021
Q2 		$16K Sell
130
-11
-8% -$1.39K ﹤0.01% 342
2021
Q1 		$19K Sell
141
-41
-23% -$5.3K ﹤0.01% 308
2020
Q4 		$23K Sell
182
-7
-4% -$821 0.01% 248
2020
Q3 		$21K Buy
+189
New +$18.8K 0.01% 268
2020
Q1 		– Sell
-240
Closed -$13K – 674
2019
Q4 		$13K Sell
240
-22
-8% -$1K ﹤0.01% 264
2019
Q3 		$10K Buy
262
+22
+9% +$954 ﹤0.01% 183
2019
Q2 		$10K Buy
+240
New +$9.94K ﹤0.01% 179

Evolution Wealth Advisors's XLRN Position: Q4 2021 in Review

Evolution Wealth Advisors sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 47 shares — an estimated $8K sold.

Evolution Wealth Advisors first reported a position in XLRN in Q2 2019 and held it in 8 quarters. The position peaked at $23K in Q4 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Evolution Wealth Advisors reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Evolution Wealth Advisors sold 47 Acceleron Pharma shares in Q4 2021, an estimated $8K.
  • Evolution Wealth Advisors first reported a position in Acceleron Pharma in Q2 2019 and held it in 8 quarters.
  • Evolution Wealth Advisors's Acceleron Pharma position peaked at $23K in Q4 2020.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Evolution Wealth Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.